TERRENO ONCOLOGICO - 2 
Terreno Oncologico - 1  +  dott. Stagnaro Sergio:
The Lancet, October 13, 2007 - "Bedside Evaluation Tobacco's action on Biological System"
http://www.thelancet.com/journals/lancet/article/PIIS0140673607614822/comments?action=view&totalComments=2#1286
Lettere scritte ed inviate dal dott. Sergio Stagnaro, a Riviste scientifiche, mediche, di settore, ecc.,
(cartacee ed online) Giornali e mass media in genere
Continua in: Pag. 2  +  Pag. 3
 

Il TERRENO ONCOLOGICO (ed e' valutabile da parte di medici appositamente istruiti) esiste, ma gli informatori, cosi come Repubblica-Salute, ed altri giornali, persino le altre riviste scienfiche importanti a livello internazionale... lo ignorano !

Ecco le prove che il Terreno Oncologico esiste:
Vegf senza controllo
Pare che siano 2 le mutazioni che compromettono la corretta inibizione dell'ormone. Così si sviluppa il tumore più diffuso fra i bambini. Lo studio è pubblicato su Nature Medicine
Ricercatori belgi e statunitensi hanno scoperto il meccanismo alla base dell'emangioma, il tumore più comune fra i bambini.
Questa neoplasia, che in Europa colpisce il 10 per cento dei neonati, prolifera nei tessuti dei vasi sanguigni e li danneggia irreversibilmente. Il tumore si sviluppa velocemente fin nei primi giorni di vita e, in molti casi, rallenta nei mesi successivi fino a scomparire del tutto verso la fine della pubertà. Sebbene si presenti in forma benigna, la malattia può avere gravi conseguenze come malformazioni e disfunzioni.
Lo studio - condotto da un gruppo di ricercatori di Harvard, del Children's Hospital di Boston e del Christian de Duve Insitute di Lovanio (Belgio), e pubblicato questa settimana su Nature Medicine - ha identificato la causa della proliferazione incontrollata delle cellule.
Nel tessuto sano, sulla superficie della cellula è presente un recettore che ha il compito di inibire l'azione dell'ormone Vegf (fattore di crescita vascolare endoteliale), che altrimenti le darebbe l’ordine di moltiplicarsi. L’analisi dei tessuti prelevati da nove diversi pazienti ha permesso di individuare due mutazioni genetiche che compromettono il funzionamento del recettore, lasciando libero l’ormone di dare avvio alla proliferazione cellulare anomala. I ricercatori hanno inoltre osservato che il tumore si origina sempre all’interno del tessuto endoteliale, lo strato che riveste la parete interna del vaso sanguigno

MicroRna: verso una nuova terapia
Testati in modelli animali, MiR-15a e miR-16-1 sembrano in grado di bloccare lo sviluppo del cancro. La ricerca italiana su Nature Medicine
Due piccoli frammenti di Rna sembrano in grado di arrestare il progresso del tumore alla prostata. Si chiamano miR-15a e miR-16-1 e sopprimerebbero l’attività di diversi oncogeni.
La scoperta si deve a un gruppo di ricercatori italiani dell’Istituto superiore di sanità (Iss) e dell’Istituto oncologico del Mediterraneo coordinati da Ruggero De Maria, ed è stata pubblicata su Nature Medicine.
Analizzando i tessuti tumorali di 40 pazienti con cancro alla prostata, i ricercatori hanno notato che una piccola porzione di DNA, normalmente localizzata sul tredicesimo cromosoma, non era presente.
In questa regione si agganciano solitamente due microRna (miR) non codificanti (che non portano cioè alla formazione di alcuna proteina), miR-15a e miR-16-1 per l’appunto, su cui si è concentrato lo studio.
Gli esperimenti effettuati sui topi hanno rivelato che la scomparsa dei due frammenti di Rna promuove la trasformazione delle cellule prostatiche in tumorali e accelera la loro proliferazione. Introdurre nuovamente nelle cellule cancerose i microRna, invece, blocca questa crescita e distrugge le cellule cancerose stesse, facendo regredire la malattia. MiR-15a e miR-16-1, secondo lo studio, sarebbero legati all’attività di tre oncogeni, Bcl2, Ccnd1 e Wnt3a, la cui espressione infatti  aumenta nei casi di tumore alla prostata.
Secondo i ricercatori, la scoperta potrebbe agevolare lo sviluppo di nuove terapie e rivelarsi utile nella diagnosi precoce: i medici potrebbero valutare l’aggressività del cancro prostatico proprio grazie alla presenza o assenza di miR-15a e miR-16-1. (a.g.)
Tratto da: Galileonet.it
vedi anche: Ruolo del DNA Mitocondriale nell'Oncogenesi

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Dear Colleagues,
I read your fascinating article, published on the "elite" peer-review Science, open to papers coming ONLY from Univeristy centres....
However, I ask me what help will be it for General Practitioners, who certainly know since two decades... that there are many other gaseous signaling molecules in biology and medicine, beside "radical" NO (if active, NO must be RADICAL: Am I right?). 
In my opinion, the present Mean Age of Medicine will continue as far as ELITE peer-reviews overlook such as advinces in CLINICAL field, like the following, really NOT RECENT !
WHAT ACCOUNT FOR THE REASON arterial compliance is impaiered, is the INHERITED alteration of endothelial function!
In addition, as s regards Hypertension pho-physiology we must consider both Hypertension Biophysical Semeiotic Constitution and hypertensive Inherited Real Risk, YOU  and Science Editors and Reviers Unfortunately ignore !
See www.semeioticabiofisica.it  +  http://www.mednat.org/cancro/terreno_oncologico.htm
But not www.nature.com, Thanks God.

for instance, See: 
http://blogs.nature.com/reports/theniche/2008/04/stemcell_skin_creams_a_san_die.html#comments
http://www.nature.com/news/2008/080130/full/451511a.html?q=2#last-comment
http://www.washingtonpost.com/ac2/wp-dyn/comments/display?contentID=AR2007041101736&start=41
http://www.nature.com/news/2008/080822/full/news.2008.1060.html?q=2#last-comment
http://blogs.nature.com/reports/theniche/2008/06/pfizer_dips_a_toe_into_cell_th.html#comments
http://www.nature.com/news/2008/080604/full/news.2008.875.html?q=2#last-comment
http://blogs.nature.com/news/thegreatbeyond/2008/09/obama_speaks_on_science.html#comments
http://blogs.nature.com/news/thegreatbeyond/2007/09/californias_new_stem_cell_supr.html

Based on my 52-year-long clinical, well-established experience I state that the evaluation of endothelial function, in every biological system, is realized nowadays also clinically with a simple stethoscope, thanks to Quantum Biophysical Semeiotics (1-10).

Unfortunately, almost all authors as well as editors (especially those of the famous Science!), ignore or overlook a reliable clinical tool useful in bedside evaluating easily and rapidly endothelial  cell functions: Biophysical Semeiotics
See http://www.semeioticabiofisica.it/microangiologia.it. 
In fact, among different techniques to evaluate the endothelium functional capacity, that depend on the amount of “radical” NO, as well as hydrogen sulfide (H2S), physiologically generated by cystathionine-lyase (CSE),  and the vasodilatation effect, nowadays there are biophysical-semeiotic methods, applicable on very large scale in a few minutes, even under stress tests. In fact, doctors may nowadays bedside assess the synthesis intensity of endothelial cell “radical” NO, as well as hydrogen sulfide (H2S), physiologically generated by cystathionine -lyase (CSE), in order to recognize both artery compliance alteration and ALL other disorders, in simple way (1-5). The percentage of vasodilation immediately after Valsalva’s Manoeuvre, confronting it with the basal value, represents the endothelial functional capacity, that is in relation to the local parenchymal cell functions, according to my Angiobiopathy theory, which complete that of Tischendorf's Angiobiotopy (11).
Taking into account that shear stress is one of the most important stimulants for the synthesis and release of “radical” NO and H2S, the non invasive technique most often  used is the transient flow-modulate “endothelium-dependent” post-ischemic vasodilatation, performed on conductance arteries such as the brachial, radial or femoral arteries. Certainly shear-stress stimulates e-NO and H2S synthesis in healthy individual, as allows me to state Biophysical Semeiotics (1-5, 8-10). In addition doctors gather a lot of other information, e.g., after drugs administration (4-8). In fact, such as vasodilatation is compared with the vasodilatation produced by drugs that are NO and  H2S donors, such as nitroglycerine, called “endothelium independent”.
The vasodilatation is quantified by measuring the arterial diameter with high resolution ultrasonography. Laser-Doppler techniques are now starting to be used that also consider tissue perfusion. One must admitt that such as methods cannot be applied neither in apparently "healthy" individual in order to perform primary prevention, neither on very large scale even in diseased subjects. All that accounts for the reason that Microcirculation and Clinical Microangiology under both physiological and pathological conditions, are scarsely known by physicians all around the world, also at universities, unfortunately.

Finally, thanks to Quantum Biophysical Semeiotics, as well as the unknown knowledge of non local realm in biological systems beside the local realm, I recently demonstrated (12-15), doctors are able in 1 second to bedside exclude macro- and micro-vessels alteration: in health, “intense” digital pressure, applied upon an artery do not bring about simultaneously aspecific gastric reflex, whereas such as reflex appears in presence of whatever vascular disorder Inherited Real Risk in individuals involved by  well-defined Biophysical-Semeiotic Constitutions (12-14)

References:
1) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it
2) Stagnaro S., Stagnaro-Neri M., Basi microcircolatorie della semeiotica biofisica. Atti del XVII Cong. Naz. Soc. Ital. Studio Microcircolazione, Firenze ott. 1995, Biblioteca Scient. Scuola Sanità Militare, 2, 94.
3) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione della compliance arteriosa e delle resistenze arteriose periferiche. Atti del XVII Cong. Naz. Soc. Ital. Studio Microcircolazione, Firenze Ott. 1995, Biblioteca Scient. Scuola Sanità Militare, 2, 93, 1995.
4) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione clinica del picco precoce della secrezione insulinica di base e dopo stimolazione tiroidea, surrenalica, con glucagone endogeno e dopo attivazione del sistema renina-angiotesina circolante e tessutale – Acta Med. Medit. 13, 99, 1997.
5) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125, 1997.
6) Stagnaro-Neri M., Stagnaro S., Sindrome di Reaven, classica e variante, in evoluzione diabetica. Il ruolo della Carnitina nella prevenzione del diabete mellito. Il Cuore. 6, 617 , 1993[Medline]
7) Stagnaro Sergio Endothelial cell function can ameliorate under safer drugs, such as Melatonin-Adenosine. BMC Cardiovascular disorders, 10 October 2004. http://www.biomedcentral.com/1471-2261/4/4/comments
8) Stagnaro S., Percussione Ascoltata degli Attacchi Ischemici Transitori. Ruolo dei Potenziali Cerebrali Evocati. Min. Med. 76, 1211, 1985 [Medline]
9) Stagnaro-Neri M., Stagnaro S., La sindrome percusso-ascoltatoria da carenza di Carnitina. Clin. Ter. 145, 135, 1994 [Medline]
10) Stagnaro-Neri M., Stagnaro S., Sindrome di Reaven, classica e variante, in evoluzione diabetica. Il ruolo della Carnitina nella prevenzione del diabete mellito. Il Cuore. 6, 617 [Medline]
11) Stagnaro Sergio.  Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php 2007
12) Stagnaro Sergio e Paolo Manzelli. Semeiotica Biofisica: Realtà non-locale in Biologia. Dicembre 2007,
www.ilpungolo.com, http://www.ilpungolo.com/leggi-tutto.asp?IDS=13&NWS=NWS5217
13) Stagnaro Sergio e Paolo Manzelli. Semeiotica Biofisica Quantistica. 
http://www.ilpungolo.com/leggi-tutto.asp?IDS=13&NWS=NWS5243
14) Stagnaro    Sergio.   Non Local Realm.  Response to Selection for Social Signalling Drives the Evolution of Chameleon Colour Change. (01 February 2008). www.plos.com,
http://biology.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pbio.0060025

I'dd appreciate your skilled answer.
Yours sincerely
By Sergio Stagnaro

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

To NCI Cancer gov. Staff, and to my friends of the list, firstly many thanks for yur kind and frank answer, I appreciate very much  (See at bottom).
However, I underscore - once again -  the present urgent necessity to  investigate both ONCOLOGICAL Terrain (OT) and  OT-dependent Inherited  Oncological Real Risk, recognized bedside rapidly with a simple stethoscope,  as do some Editors in worthwhile manner.
In the exclusive interest of "mankind", we all must state if these  oncological concepts are FALSE or TRUE, without further, distressing,  disheartening, disappointing DELAY (I can document what I state, of course).
In a few words, ONCOLOGICAL Authorities, like NCI, have to STATE now - and  not tomorrow - if MY OLD concepts as ONCOLOGICAL Terrain (OT) and  OT-dependent Inherited Oncological Real Risk have been corroborated or  falsify... In the later case, obviously undermining  HOW and Why, in my  PRESENCE, of course.

I state, once more, responsebly that without ONCOLOGICAL Terrain (OT) and  OT-dependent Inherited Oncological Real Risk in UTERI CERVIX cervical  carcinoma is NOT possible, in spite of type 16, and 18 HPV !

Before every study in this direction,  we all, INCLUDING peer-reviews  "skilled" referees, MUST know what "newborn-pathological, type I, subtype a)  ONCOLOGICAL, Endoarteriolar Blocking devices really mean (For instance, read  Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices in  Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The  Lancet. March 06 2007.
http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?totalcomments=1) !
For precise information on this ovelooked, paramount topic, See  Bibliography, Oncological Terrain, a.s.o.

Let's all remember that, while we are writing KIND and WISE mails, INNOCENT  individuals, apparently healthy... but positive for ONCOLOGICAL Terrain (OT)  and  OT-dependent Inherited Oncological Real Risk in some biological system,  are involved by CANCER, and .... sometimes... die, too !

I am awaiting yours kind answer, and that of list MEMBERS. Many Thanks to  all of you.
Kind regards
By Sergio Stagnaro

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

----- Original Message -----
From: "NCI Cancer.gov Staff" <[email protected]>
To: <[email protected]>
Sent: Tuesday, October 21, 2008 11:34 PM
Subject: RE: Cancer.gov Inquiry - HPV cause of Cervical Cancer!


10/21/08_45321PIQ

Thank you for your e-mail to the National Cancer Institute (NCI) regarding the human papillomavirus (HPV) and cervical cancer.  In your e-mail, you asked if HPV can cause cervical cancer in women without oncological terrain and inherited real risk.  The NCI, a component of the National Institutes of Health, is the United States' principal agency for cancer research.  NCI e-mail staff are not familiar with the term "oncological terrain."  However, we can offer information about HPV and cervical cancer that you may find useful.

We encourage you to explore these resources:

--"PDQ(R) Treatment Summary for Health Professionals on Cervical Cancer":  This summary of information from PDQ, the NCI's comprehensive cancer information database, discusses treatment options for cervical cancer and outlines treatment by stage.  This resource is available at http://www.cancer.gov/cancertopics/pdq/treatment/cervical/healthprofessional/  on the Internet. 
In particular, you may wish to refer to the
section on HPV infection and cervical cancer at
http://www.cancer.gov/cancertopics/pdq/treatment/cervical/HealthProfessional/page2 on the Internet.

--"Novel Genetic Test Predicts the Development of Cervical Cancer":
This article on the NCI's Center for Cancer Research Web site discusses a study that looked at the use of a biomarker that would allow doctors to discern lesions with low and high-risk for cervical cancer disease progression.  This article can be found at
http://ccr.cancer.gov/news/frontiers/january2007/pdfs/article_ried.pdf on the Internet.

You will need Adobe Acrobat(r) Reader to view the PDF (Portable Document Format) file mentioned above.  If you do not already have Adobe Acrobat Reader, you can download the free software at
http://www.adobe.com/products/acrobat/readstep2.html on the Internet.

You may also wish to perform a search of the medical literature for published articles about HPV and cervical cancer.  The PubMed(R) database is a service of the National Library of Medicine (NLM), a component of the National Institutes of Health (NIH)PubMed provides a free search tool to help people find journal articles of interest in the health and medical sciences.  PubMed can be found at http://www.pubmed.gov on the Internet.
We hope this information is helpful.

National Cancer Institute

NOTE:  Should you get an error message when clicking on the URL link(s) in this e-mail, you may have more success opening the link if you copy and paste the full URL into your browser window.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

-----Original Message-----
From: [email protected]
[mailto:[email protected]]
Sent: Monday, October 13, 2008 8:05 AM
To: NCI Cancer.gov Staff
Subject: Cancer.gov Inquiry - HPV cause of Cervical Cancer !

Message: I ask if HPV can bring about cervical Cancer also in women WITHOUT Oncological Terrain "AND" Inherited Oncological Real Risk in Uterus Cervix ?
By Sergio Stagnaro MD

P.S.
See and read:
Quantum Biophysical Semeiotics and Cancer Inherited Real Risk in www.nature.com:
http://blogs.nature.com/news/thegreatbeyond/2008/07/newsweak_darwin_vs_lincoln.html#comments
http://blogs.nature.com/nm/spoonful/2008/07/product_placement.html#comments
http://network.nature.com/forums/askthenatureeditor/1846?page=1#reply-5181
http://blogs.nature.com/nm/spoonful/2008/05/our_new_columns_narrowing_thehtml#comments
and specially
http://blogs.nature.com/nm/spoonful/2008/04/stress_as_a_therapy_1.html#comments
http://blogs.nature.com/news/thegreatbeyond/2008/07/new_drug_for_prostate_cancer_e.html#comments
http://blogs.nature.com/nature/journalclub/2008/02/nicholas_katsanis.html#comments
http://blogs.nature.com/nm/spoonful/2008/08/the_best_defense_against_biowa.html#comments
http://blogs.nature.com/news/thegreatbeyond/2008/08/bush_going_green_in_the_deep_b.html#comments
http://www.nature.com/news/2008/080828/full/news.2008.1068.html?q=2#last-comment
http://www.nature.com/news/2008/080902/full/news.2008.1076.html?q=2#last-comment
http://www.nature.com/news/2008/080917/full/news.2008.1116.html?q=2#last-comment
http://www.nature.com/news/2008/080923/full/news.2008.1124.html?q=2#last-comment
http://blogs.nature.com/news/thegreatbeyond/2008/10/election_watch.html#comments

Commento NdR: